15.88
Novocure Ltd stock is traded at $15.88, with a volume of 1.96M.
It is down -6.20% in the last 24 hours and up +50.52% over the past month.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
See More
Previous Close:
$16.93
Open:
$16.75
24h Volume:
1.96M
Relative Volume:
1.00
Market Cap:
$1.84B
Revenue:
$674.41M
Net Income/Loss:
$-173.05M
P/E Ratio:
-10.35
EPS:
-1.5343
Net Cash Flow:
$-48.07M
1W Performance:
+31.02%
1M Performance:
+50.52%
6M Performance:
+36.78%
1Y Performance:
-10.59%
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NVCR
Novocure Ltd
|
15.88 | 1.96B | 674.41M | -173.05M | -48.07M | -1.5343 |
|
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
|
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher - Sahm
Wells Fargo Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $17 - Moomoo
NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook - Sahm
NovoCure Limited Surges As Guidance Hike Fuels NVCR Rally - timothysykes.com
Here's What Analysts Are Forecasting For NovoCure Limited (NASDAQ:NVCR) After Its First-Quarter Results - Moomoo
NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
NovoCure Ltd (NVCR) Shares Surge 9.3% -- What GF Score of 70 Tel - GuruFocus
NovoCure (NASDAQ:NVCR) Trading 6.8% HigherShould You Buy? - MarketBeat
NVCR Maintained by Evercore ISI Group -- Price Target Raised to $20 - GuruFocus
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $20 - Moomoo
NovoCure Ltd (NVCR) Q1 2026 Earnings Call Highlights: Revenue Gr - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses - simplywall.st
MSN Money - MSN
NovoCure Earnings Call Highlights Growth, One-Time Hit - TipRanks
NovoCure Limited Q1 2026 Earnings Call Summary - Yahoo Finance
NovoCure (NASDAQ:NVCR) Announces Earnings Results - MarketBeat
NovoCure Ltd Q1 2026 Financial Results: Revenues, Losses, and Key Forward-Looking Statements - Minichart
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
NovoCure (NVCR) Q1 2026 Earnings Transcript - The Globe and Mail
NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA A - GuruFocus
Novocure (NVCR) Shares Jump 22% on Strong Q1 Revenue and Raised Outlook - GuruFocus
NovoCure (NASDAQ:NVCR) Shares Gap UpShould You Buy? - MarketBeat
NovoCure: Q1 Earnings Snapshot - theheraldreview.com
Novocure (NVCR) Reports Strong Q1 Revenue Growth - GuruFocus
NVCR Stock Update: Insights on Current Market Trends - GuruFocus
Novocure Jumps On Q1 Revenue Growth; Lifts FY26 Revenue Guidance - RTTNews
NovoCure (NVCR) Q1: EPS -0.62 (miss vs -0.51 est.), Revenue $174 - GuruFocus
NovoCure Reports Revenue Growth Driven by New Pancreatic Cancer Therapy - HarianBasis.co
NovoCure Q1 Earnings Call Highlights - MarketBeat
NovoCure Limited 2026 Q1ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-04-30 - Seeking Alpha
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
NovoCure Ltd reports first quarter 2026 earnings performance - Traders Union
Novocure reports Q1 2026 revenue $174.1M, adjusted EBITDA $(0.3)M, net loss $71.1M - TradingView
Novocure (NASDAQ: NVCR) grows Q1 revenue and raises 2026 outlook - Stock Titan
NovoCure (NASDAQ: NVCR) grows Q1 2026 revenue while investing in new cancer indications - Stock Titan
New pancreatic cancer launch helps Novocure reach $174M in Q1 revenue - Stock Titan
Novocure earnings in focus as new pancreatic therapy debuts By Investing.com - Investing.com Nigeria
Novocure earnings in focus as new pancreatic therapy debuts - Investing.com UK
NovoCure (NASDAQ: NVCR) director converts options into 21,500 shares - Stock Titan
Vanguard (NVCR) holds 6.34M shares, 5.57% stake disclosed in 13G - Stock Titan
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Earnings Preview: Novocure to Report Financial Results Pre-market on April 30 - Moomoo
CEO Frank Leonard's new NovoCure (NASDAQ: NVCR) contract outlines pay - Stock Titan
NovoCure (NVCR) to Release Quarterly Earnings on Thursday - MarketBeat
NovoCure Ltd (NVCR) Stock Up 6.5% and Still Undervalued -- GF Sc - GuruFocus
NovoCure : Financial Reports 2026 novocure corporate responsibility report - marketscreener.com
Total debt per share of NovoCure Ltd. – SWB:038 - TradingView
NovoCure Ltd stock (JE00B6T5S470): Is tumor treating fields therapy strong enough to unlock new upsi - AD HOC NEWS
[DEF 14A] NovoCure Ltd Definitive Proxy Statement - Stock Titan
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):